Sun Pharma Advanced Research Company Limited (SPARC.NS) NSE

198.98

-5.26(-2.58%)

Updated at June 03 01:22PM

Currency In INR

Key Executives

Name	Title	Pay	Year Born
Anilkumar Raghavan	Chief Executive Officer	0	1968
Anup Rathi	Chief Financial Officer	15.14M	N/A
Nitin Dharmadhikari	Chief Operating Officer	0	1962
Nitin K. Damle	Executive Vice President of Biologics & Chief Innovation Officer	0	N/A
Jaydeep Issrani	Senior General Manager of Business Development, Corporate Communication & Investor Relations	0	N/A
Shanta Gupta	Chief Human Resource Officer	0	N/A
Narendra Lakkad	Head of Corporate Development & Operations Management	0	N/A
Vikram Ramanathan	Head of Drug Discovery & Preclinical Development	0	N/A
Yashoraj Zala	Head of Drug Delivery Systems	0	N/A
Siu-Long Yao	Head Clinical Development	0	N/A
Kajal Damania	Company Secretary & Compliance Officer	0	N/A

Name

Title

Pay

Year Born

Anilkumar Raghavan

Chief Executive Officer

1968

Anup Rathi

Chief Financial Officer

15.14M

N/A

Nitin Dharmadhikari

Chief Operating Officer

1962

Nitin K. Damle

Executive Vice President of Biologics & Chief Innovation Officer

N/A

Jaydeep Issrani

Senior General Manager of Business Development, Corporate Communication & Investor Relations

N/A

Shanta Gupta

Chief Human Resource Officer

N/A

Narendra Lakkad

Head of Corporate Development & Operations Management

N/A

Vikram Ramanathan

Head of Drug Discovery & Preclinical Development

N/A

Yashoraj Zala

Head of Drug Delivery Systems

N/A

Siu-Long Yao

Head Clinical Development

N/A

Kajal Damania

Company Secretary & Compliance Officer

N/A

Description

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited